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RE-HOSPITALIZATION RATES OF ACUTE CORONARY SYNDROME PATIENTS IN
REAL WORLD CLINICAL PRACTICE: OBSERVATIONS FROM A NATIONAL
ADMINISTRATIVE CLAIMS DATA
Tunceli O1, Gandhi SK2, Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1,
Singer J1
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
OBJECTIVES: Re-hospitalization andmortality rates are increasingly being used as
quality of care measures that have significant reimbursement implications. We
examine the rates of re-hospitalization and mortality of acute coronary syndrome
(ACS) patients in real-world clinical practice. METHODS: Commercially-insured
patients (age18 years) with an inpatient hospitalization for ACS [ICD-9-CM codes
for acute myocardial infarction or unstable angina (UA)] between 1/1/2007-5/31/
2010 were identified from medical claims in the HealthCore Integrated Research
Database (HIRD). Patients with ACS events within one year prior to index hospital-
izationwere excluded. All-cause andACS-related re-hospitalizations andmortality
rates within 30 days and 12months after index event were evaluated. RESULTS:Of
66,772 ACS patients (60%male; mean age 66.6 years), 21% had diagnostic coding for
ST elevation myocardial infarction (STEMI), 31% had coding for non-ST elevation
myocardial infarction (NSTEMI), 37% had UA, and 11% had not otherwise specified
(NOS) ACS. Approximately, 90% and 52%of patients had30-days and 12months
of continuous eligibility respectively. The 30-day all-cause re-hospitalization rate
was 16.3 % (STEMI: 16.4%, NSTEMI: 19.0%, UA: 13.3%, NOS: 20.6%;) and 6.3 % (STEMI:
8.8%, NSTEMI: 6.6%, UA: 5.2%, NOS: 4.5%) for anACS-related re-hospitalization. The
12-month all cause re-hospitalization rate was 41.3% (STEMI: 39.0%, NSTEMI:
46.4%, UA: 38.2%NOS: 46.6%, )and 16.6% for an ACS-related re-hospitalization. The
30-day post-index mortality rate was 2.4 % (STEMI:1 .8%, NSTEMI:4.3%, UA:0.5%,
NOS:5.2%;) and the 12-month rate was 7.0%. For patients with ages  65 years, the
30-day all-cause and ACS-related re-hospitalization rates were 21.2% and 7.0%,
respectively. CONCLUSIONS: The re-hospitalization and mortality rate for ACS
patients within 30 days and 12-months post-index hospitalization discharge as
observed in real-world clinical practice remain high. Use of more effective thera-
pies may provide an opportunity to improve important clinical and economic out-
comes in ACS patients.
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IDENTIFYING EFFICIENT ACUTE CLINICAL PATHWAYS FOR CHEST PAIN: USING
RISK ADJUSTED COST-EFFECTIVENESS (RAC-E) TO COMPARE HOSPITALS USING
LINKED, ROUTINELY COLLECTED DATA
Caffrey O1, Pham C2, Karnon J2, Ben-Tovim DI3, Hakendorf P3, Crotty M4
1University of Birmingham, Birmingham, Warwickshire, UK, 2University of Adelaide, Adelaide,
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OBJECTIVES: Cost-effectiveness analysis is now well established in relation to the
evaluation of health technologies, but not in relation to broader institutional level
variations in clinical pathways. Linked, routinely collected data provides an oppor-
tunity to evaluate real world activity. A novel approach to analysing the risk-ad-
justed cost-effectiveness (RAC-E) of acute services for patients presenting with
chest pain at the four main public hospitals in South Australia is presented.
METHODS: Routinely collected data on hospital separations (including costs) and
mortality records were linked deterministically. Relevant intermediate endpoints
over a two year follow-up period in a cohort of patients presenting with chest pain
in the year to July 2006 were identified. Lifetime costs and survival were extrapo-
lated from these endpoints using data fromchest pain patients presenting between
July 2002 and June 2008. The resulting estimates of costs and survival were stan-
dardized using separate regression models that estimated expected cost and sur-
vival values for each patient. RESULTS: In the base case, two of the four hospitals
were dominated by hospital 1. Hospital 2 had lower standardized lifetime costs
than hospital 1, and the incremental cost per life year gained between these two
hospitals was Aus$2,909. A bootstrapped probabilistic sensitivity analysis showed
hospital 1 to have very high probabilities of cost-effectiveness at relevant dollar
values for a life year gained. Analysis of differences in cost components between
the hospitals showed that hospital 1 spent relatively less on pathology and imag-
ing, whilst spending more on nursing time and pharmaceuticals. CONCLUSIONS:
RAC-E provides a useful framework for identifying important differences in the
costs and benefits associated with variations in clinical practice. Potential deter-
minants can be partially investigatedwith the data, but further primary analysis of
clinical pathways at key hospitals is required to fully inform the dissemination of
best practice.
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CARDIOVERSION TREATMENT PATTERNS AND OUTCOMES AMONG ACUTE
ATRIAL FIBRILLATION PATIENTS IN 5 EUROPEAN COUNTRIES
Buono JL1, Russell T2, Worsfold A2, Bash LD3
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OBJECTIVES: We examine current treatment patterns associated with the use of
antiarrhythmics for pharmacologic cardioversion and evaluate time to conversion
among patients with acute atrial fibrillation (AF) in France, Italy, Germany, Spain,
and UK.METHODS: Data were collected cross-sectionally as observed by 303 phy-
sicians from April to June 2010. RESULTS: Among 2,997 patients, 1,352 (45%) re-
ceived pharmacologic cardioversion only, with 1,082 (80%) successfully cardiovert-
ing. Of these, 931 (69% of those treated pharmacologically, 86% of those
successfully) had complete information on time to achieve sinus rhythm andwere
further assessed here. Amiodarone was administered to most (49%), with similar
proportions receiving intravenous (IV) (53%) and oral (46%) formulations. Amioda-
rone IV was associated with a significantly shorter median conversion time (8
hours) compared to oral (36 hours). Patients treated with flecainide (26%) had the
shortest median time to cardioversion (4 hours), while patients on propafenone
(15%) were next (6 hours). Median cardioversion time varied by country. Specifi-
cally, patients in France took longer to convert on amiodarone IV and oral at a
median time of 12 and 48 hours compared to an average of 7 and 24 hours, respec-
tively, in other countries. In Germany, little difference was observed with median
conversion times of 9 and 10 hours for amiodarone IV and oral, respectively. Me-
dian conversion times were also similar between amiodarone IV and flecainide in
Spain and Italy (a difference of 1 and 2 hours, respectively) compared to an average
difference inmedian conversion time of 4 hours between these treatments overall.
CONCLUSIONS: While amiodarone had a longer median time to cardioversion,
faster acting agents, such as flecainide and propafenone, had conversion times
substantially longer than their known time of action, reflecting other influences on
treatment administration. Differences in conversion time suggest country- and
physician-specific practices in the use of pharmacologic cardioversion therapies.
Cardiovascular Disorders – Research on Methods
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BEYOND CASE FATALITY: A NEW METHOD TO ESTIMATE THE EFFECT OF
INCREASING TREATMENT UPTAKE ON MORTALITY
Mitsakakis N1, Wijeysundera HC2, Krahn M1
1Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON,
Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada
OBJECTIVES: Epidemiological models have been widely used to estimate how in-
creased uptakes of medical and surgical treatments affect mortality and related
outcomes. Standard methods rely on the estimate of the case fatality, defined as
the risk of death in the absence of the treatment. Because most patients receive
some treatment, mortality rates where some treatment is present are often used
instead of case fatality rates, leading to biased results. A method that does not rely
on case fatality estimates is needed. METHODS: We borrow the mechanism used
for the calculation of the Potent Impact Fraction (PIF), an epidemiological measure
that is equal to the proportional reduction in the incidence of a disease ormortality,
resulting froma specific change in the distribution of a risk factor in the population,
and apply it to the estimation of the relative reduction of mortality caused by the
increase of treatment uptake in the population at risk. We apply this method to
estimate the reduction of cardiovascular disease deaths in Ontario, if treatment
rates for CHD interventions were to be increased from 2005 levels to the recom-
mended benchmark utilization of 90%. TheMant-Hicksmodel for polypharmacy is
adopted, while the uptakes of multiple treatments are assumed to be independent
from each other. RESULTS: Using the proposed PIF-based method, we estimated
that increasing treatment to benchmark levels uptake results in a reduction of
cardiovascular mortality of 22.5%. The standard method gives a reduction of 17%,
probably due to underestimation of the case fatality.CONCLUSIONS:Herewe pres-
ent an alternative method for the estimation of the effect of treatment uptake
increase to the reduction ofmortality. Our example suggests that themagnitude of
bias associated with the standard method may be substantial. This approach may
be a useful tool for epidemiological and health care research.
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DEVELOPMENT AND VALIDATION OF A SHORT PRO MEASURE OF HEALTH
STATUS FOR INDIVIDUALS WITH ACUTE MYOCARDIAL INFARCTION: THE
MYOCARDIAL INFARCTION DIMENSIONAL ASSESSMENT SCALE (MIDAS)
Jenkinson C1, Thompson D2, Roebuck A3, Churchman D4
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OBJECTIVES: To develop and validate a disease-specific health status measure for
individuals with myocardial infarction (MI). METHODS: The development of the
Myocardial Infarction Dimensional Assessment Scale (MIDAS) followed threemain
stages. Stage 1 consisted of in-depth, semi-structured, exploratory interviews con-
ducted on a sample of 31 patients to identify areas of salience and concern to
patientswithMI. These interviews generated 48 candidate questions. In stage 2 the
48-item questionnaire was used in a postal survey to identify appropriate rephras-
ing/shortening, to determine acceptability and to help identify sub-scales of the
instrument addressing different dimensions of MI. Finally, in stage 3 the construct
validity of MIDAS subscales was examined in relation to clinical and other health
outcomes. Setting - A single centre (district general hospital) in England was used
for stages 1 and 3 and a national postal surveywas conducted for stage 2. Patients - A
total of 410 patients were recruited for the national survey (stage 2). Full data was
available on 348 (85%) patients. 155 patients were recruited to test construct valid-
ity (stage 3). RESULTS: The MIDAS contains 35 questions measuring seven areas of
health status: physical activity, insecurity, emotional reaction, dependency, diet,
concerns overmedication and side effects. Themeasure has high face, internal and
construct validity and is likely to prove useful in the evaluation of treatment re-
gimes for MI. CONCLUSIONS: The MIDAS has acceptable validity and reliability. It
is suitable for use in a variety of settings for patients with myocardial infarction.
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OBJECTIVES: To identify response shift using two structural equation modeling
(SEM) techniques with the SF-36 Health Survey.METHODS: Hypertensive patients
with coronary artery disease (CAD) who completed both baseline and one year
follow-up of the SF-36 were included (n909). An occurrence of response shift
using Oort and Schmitt SEM techniqueswas specifically identified. LISREL software
was used to conduct SEM procedures. A variety of fit indices were used to deter-
mine model fit. For both SEM approaches, response shift is defined based on
changes in various parameters in themeasurementmodel. Effect size indices were
calculated for the contribution of response shift on the change of SF-36 domains
scores.We hypothesized the divergence in defining type of response shift linked to
changes in various parameters will lead to different findings. RESULTS: Only the
SF-36 physical functioning (PF) scale was identified with recalibration response
shift by using both Oort and Schmitt SEM approaches. With Oort approach, recali-
bration was identified by the change in intercepts, whereas Schmitt approach de-
fines recalibration as the change in factor variances or factor loadings over time.
Effect size of the recalibration response shift on the change of PF domain scores
was marginal: 0.118. CONCLUSIONS: This is the first study to identify response
shift in hypertensive CAD patients using SEM approach. Recalibration response
shift was identified using both Oort and Schmitt SEM approaches. Different inter-
pretation of specific PF items by hypertensive CAD patients before and after treat-
ments may contribute to the recalibration response shift. By looking more closely
at the SF-36 PF domain scores among hypertensive CAD patients will enable us to
provide nuanced attention and direct treatment for the most impaired aspects of
quality of life.
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EXTENSION OF META-ANALYSIS IN COMPARING OF FIMASARTAN WITH
LOSARTAN IN BLOOD PRESSURE LOWERING EFFECT
Na Y, Lee EK
Sookmyung Women’s University, Seoul, South Korea
OBJECTIVES: A new drug fimasartan had been developed and currently approved
in Korea for treating essential hypertension. This study aimed to identify whether
main results of direct comparative study maintains consistency with those of ex-
tension of meta-analysis in the blood pressure lowering effect of fimasartan with
losartan. METHODS: Systematic reviews of literatures of clinical trials including
fimasartan or losartan were conducted. The blood pressure change from baseline
were used as an effectiveness measure and was pooled in RevMan 4.0. For direct
comparison, the head-to-head randomized controlled trial (RCT) of fimasartan and
losartan was used. For indirect comparison, it followed to method of adjusted
indirect comparison (Bucher 1997) using common comparator and used ITC (Indi-
rect Treatment Comparison) program (CADTH). In addition, Bayesian mixed treat-
ment comparison (MTC) was performed on which combines whole pairwise com-
parison studies together by WinBugs program. After that, the results were
compared with that of a direct comparison. RESULTS: In regard to direct compar-
ison, there is the only head-to-head trial (Phase III) report of comparing fimasartan
with losartan, which had conducted locally. For indirect comparison, the search
identified one report of the trial of comparing fimasartan with placebo (Phase IIb),
and the 6 of articles of comparing losartan with placebo were selected and mea-
sured estimateswere pooled. The change in reduction in diastolic blood pressure of
losartan and fimasartan versus placebo was 2.7 mmHg as direct estimate re-
trieved from RCT, and3.315 mmHg as combined estimate through MTC analysis,
respectively. In SBP reduction, it was 4.3 mmHg and 3.995 mmHg respectively.
CONCLUSIONS: This study found that estimates obtained from indirect compari-
son were similar with those of direct. The results from the two comparison meth-
ods both indicated consistently that the antihypertensive effect of fimasartan is
better than losartan.
Sensory Systems Disorders – Clinical Outcomes Studies
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STEVENS-JOHNSON AND RED MAN SYNDROME: A CASE REPORT ON ADVERSE
DRUG REACTIONS OF SIMULTANEOUS USE OF PHENYTOIN AND VANCOMYCIN
Kler SK
Department of General Medicine, Government Medical College & Hospital, Chandigarh, India
OBJECTIVES: Adverse drug reactions (ADRs) are a common cause of injury to hos-
pitalized patients and are likely preventable.Monitoring spontaneous adverse drug
reactions is one of the epidemiological methods for assessing the safety of drugs in
a hospital setting. Many studies reported that cutaneous reactions and gastroin-
testinal disturbances as top most reported ADRs.METHODS: The author reports a
case of 22-year-old girl who developed Stevens-Johnson syndrome and Red Man
syndrome after receiving phenytoin and vancomycin simultaneously. RESULTS:
This was 22 year old girl presented with chief complaints of headache, nausea,
vomiting and sweating. Diagnosed as a case of post fossa tumor and operated on 3rd
day after admission. She was treated with different medications along with van-
comycin 1gm 12hourly, phenytoin 100mg 8 hourly and dexamethasone 2gm 8
hourly. On the day 15 of vancomycin and phenytoin treatment, the patient devel-
oped diffuse polymorphic erythemawithmouth lesions and typical palmo-plantar
lesions characteristic of Stevens-Johnson syndrome. Also a skin rash and lesions
predominantly on the face, neck, upper back and front regions characterized as Red
Man syndrome. Use of vancomycin and phenytoin was discontinued and replaced
by cefipime plus linizolid and phenobarbitone respectively. The reaction persisted
for approximately 55 days with progressive improvement and the patient was
treated with hydroxyzine 30mg, 6 hourly, hydrocortisone 100mg, 6 hourly with
gradual tapering of the dose and topical treatment of the lesions. CONCLUSIONS:
Although there are reports on the of adverse drug reaction with monotherapy of
phenytoin and vancomycin or in involvement with other medications. However,
there are no reports on the development of Stevens-Johnson and Red man syn-
drome when phenytoin and vancomycin were used simultaneously with other
drug treatment. It also confirms the possible increased risk of developing Stevens-
Johnson syndrome when phenytoin is associated to corticosteroids.
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DIAGNOSED AND UNDIAGNOSED DRY EYE, SYMPTOM SEVERITY, AND
ASSOCIATED FACTORS AMONG MEN AND WOMEN IN THE UNITED STATES
Schaumberg DA1, Li JZ2
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OBJECTIVES: To examine factors associated with dry eye disease (DED) in the US.
METHODS: We conducted a cross-sectional survey of 4000 participants in the
Women’s Health Study and Physicians’ Health Studies with diagnosed DED or
severe symptoms. We assessed the current level of symptoms by the Ocular Sur-
face Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE) question-
naires, diagnosis, co-morbidities, treatments, and patient satisfaction. RESULTS:
3390 (84.8%) subjects returned questionnaires. 2099 participants reported a diag-
nosis of DED, and 1291 denied DED diagnosis (73.9% of these had reported DED
diagnosis previously). Among 451 subjects selected based on severe symptoms
alone, 114 (25.3%) reported a new diagnosis of DED, which was more strongly
associated with severe symptoms by SANDE40 (OR2.24, p0.001), than by OSDI
33-100 (OR1.38, p0.25). Blepharitis (OR2.03, p0.05) was also associated with
new DED diagnoses. Among those who currently denied DED diagnosis, 15.9% had
severe (SANDE40) and 40.4% had mild-moderate symptoms (SANDE 15-40). Ad-
justing for age and sex, participants with symptoms only were less likely than
diagnosed patients to have an eye exam 1x/year (OR0.71, p0.002), use antide-
pressants (OR0.76, p0.04), artificial tears (OR0.67, p0.0002), or other DED
treatments (OR0.65, p0.0001); and more likely to report refractive surgery
(OR1.67, p0.02), and contact lens wear (OR2.51, p0.0001). In age- and sex-
adjusted models including all respondents, those who currently reported DED di-
agnoses were more likely to have an eye exam 1x/year (OR1.42, p0.0003),
severe symptoms (SANDE 40, OR2.00, p0.0001), blepharitis (OR1.41,
p0.007), use antidepressants (OR1.43, p0.003), artificial tears (OR2.01,
p0.0001), or other DED treatments (OR1.70, p0.0001); and less likely to use
glaucomamedications (OR0.82, p0.02).CONCLUSIONS:These observations sug-
gest the possibility of under-diagnosis of DED, and are also consistentwith amilder
and/or more intermittent type of DED. Individuals with diagnosed DED are more
likely to have severe symptoms, despite therapy.
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PERSISTENCE WITH STATINS AND THE RISK OF AGE RELATED MACULAR
DEGENERATION IN A LARGE HEALTH ORGANIZATION IN ISRAEL
Chodick G, Shalev V, Goldstein I, Sror M
Maccabi Healthcare Services, Tel Aviv, Israel
OBJECTIVES: To investigate the association between persistent use of statins and
the risk of age-related macular degeneration (AMD). METHODS: A population-
based retrospective cohort among adults who began statin therapy between 1998
and 2006 in a large health organization in Israel. The organization’s central com-
puterized databases were used to collect sata on incident AMD cases diagnosed by
ophthalmologists. RESULTS: A total of 108,973 individuals aged 55 or older were
identified. During the study follow-up period 409,113 person-years, there were
2,732 incident AMD cases (6.68 per 1,000 person-years). The crude incidence den-
sity rate of AMD among patients at the lowest quintile of persistence with statins
(7.18 per 1,000) was comparable to that of highest persistence quintile (7.13 per
1,000). After adjustment for potential confounders, patients in the highest quintile
of persistence with statins had a hazard ratio of 0.99 (95% CI: 0.78-1.26) for AMD
compared with patients in the lowest PDC quintile. In addition to age, AMD was
found to associate with past smoking, asthma, diabetes and frequent visits to
ophthalmologists or primary physicians prior to index date. CONCLUSIONS: Our
study agrees with previous studies that showed no association between persistent
use of statins and reduced risk of AMD. These results suggest that the early reports
on a strong protective effect of statins against AMD development, were probably a
result of a small study effect.
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SYSTEMATIC REVIEW OF THE EPIDEMIOLOGIC LITERATURE ON ATOPIC
DERMATITIS IN CHILDREN
Berbari J1, Reynolds S1, Heil-Ruess M2, Iskedjian M3
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OBJECTIVES: A systematic review of the literature was performed to gather the
epidemiological evidence related to atopic dermatitis (AD) in a pediatric
population. METHODS: OVID MEDLINE® was searched using terms related to AD,
epidemiology, incidence/prevalence in a population 18 years old. Two research-
ers undertook the inclusion/exclusion process on the 466 citations that had been
identified. A third person acted as an overall reviewer and adjudicator. RESULTS:
The major finding was the International Study of Asthma and Allergies in Child-
hood (ISAAC)which reported the prevalence of AD in children 6-7 years old from 35
countries at two distinct time periods (around 1995 and 2002). A further 32 inde-
pendent studieswere identified for inclusion in this review. These studies reported
on incidence (n2), prevalence (n25) or both (n5) in Europe (n23), Southeast
Asia (n8) and Africa (n1). The number of study participants differed greatly
(n137 to n317,926). According to ISAAC, the worldwide prevalence rate of AD
increased by a rate of 36% from 12.9% in 1995 to 17.5% in 2002. Over that same time
period, a 46% increase was reported for North America and Western Europe with
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